News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,262 Results
Type
Article (42261)
Company Profile (436)
Press Release (670565)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208714)
Career Advice (2021)
Deals (36003)
Drug Delivery (104)
Drug Development (83567)
Employer Resources (173)
FDA (16422)
Job Trends (15092)
News (352747)
Policy (33072)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50932)
ALS (92)
Alzheimer's disease (1422)
Antibody-drug conjugate (ADC) (127)
Approvals (16412)
Artificial intelligence (257)
Autoimmune disease (24)
Automation (15)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (273)
Cancer (2151)
Cardiovascular disease (179)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (427)
Cervical cancer (19)
Clinical research (67641)
Collaboration (840)
Compensation (522)
Complete response letters (24)
COVID-19 (2642)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2087)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (263)
Diagnostics (6408)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (105)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87580)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115463)
Executive appointments (714)
FDA (17635)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (755)
Gene editing (109)
Generative AI (20)
Gene therapy (312)
GLP-1 (738)
Government (4494)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (124)
Indications (28)
Infectious disease (2785)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (92)
Interviews (311)
IPO (16776)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (36)
Layoffs (490)
Leadership (17)
Legal (7983)
Liver cancer (73)
Lung cancer (309)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (292)
MASH (65)
Medical device (13496)
Medtech (13501)
Mergers & acquisitions (19741)
Metabolic disorders (694)
Multiple sclerosis (77)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1966)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2571)
Now hiring (38)
Obesity (377)
Opinion (223)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (225)
Patient recruitment (100)
Peanut (47)
People (58599)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21250)
Phase II (29844)
Phase III (22076)
Pipeline (1140)
Policy (138)
Postmarket research (2601)
Preclinical (9070)
Press Release (67)
Prostate cancer (101)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (397)
Real estate (6014)
Recruiting (66)
Regulatory (22675)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2222)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (26)
The Weekly (47)
United States (22646)
Vaccines (689)
Venture capitalists (40)
Weight loss (250)
Women's health (36)
Worklife (16)
Date
Today (69)
Last 7 days (482)
Last 30 days (2274)
Last 365 days (33879)
2025 (9544)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27993)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (237)
Arkansas (14)
Asia (39182)
Australia (6525)
California (5928)
Canada (1956)
China (505)
Colorado (260)
Connecticut (275)
Delaware (139)
Europe (85586)
Florida (866)
Georgia (203)
Idaho (57)
Illinois (532)
India (25)
Indiana (305)
Iowa (11)
Japan (152)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (879)
Massachusetts (4520)
Michigan (217)
Minnesota (385)
Mississippi (2)
Missouri (80)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1697)
New Mexico (30)
New York (1683)
North Carolina (1005)
North Dakota (7)
Northern California (2571)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1321)
Puerto Rico (11)
Rhode Island (32)
South America (1110)
South Carolina (20)
South Dakota (1)
Southern California (2222)
Tennessee (99)
Texas (880)
Utah (175)
Virginia (141)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
713,262 Results for "propella therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Astellas to Acquire Propella Therapeutics
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Propella Therapeutics, Inc. (President and CEO: William Moore, “Propella”) today announced that Astellas, through a U.S. subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will acquire Propella.
November 15, 2023
·
5 min read
Deals
Astellas Completes Acquisition of Propella Therapeutics
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced today that it has completed the acquisition of Propella Therapeutics, Inc. (President and CEO: William Moore, “Propella”), and has become a wholly owned subsidiary of Astellas as of U.S. Eastern Time December 21, 2023.
December 21, 2023
·
3 min read
Deals
Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas Pharma
Outcome Capital, a highly specialized life sciences advisory and investment banking firm, announced that Propella Therapeutics, a biopharmaceutical company that has developed a platform for lymphatic targeting to create best- or first-in-class oncology drugs, has been acquired by Astellas Pharma.
January 4, 2024
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
·
4 min read
Bio NC
Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced that Dr. Jose Avitia of the New Mexico Cancer Center will present updated data from the Company’s ongoing Phase 1/2a study of PRL-02 for the treatment of advanced prostate cancer on Thursday Feb 16 from 11:30AM to 1:00PM PST at the 2023 ASCO Genitourinary (GU) Cancers Symposium.
February 14, 2023
·
7 min read
Press Releases
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
March 26, 2025
·
4 min read
Press Releases
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 9, 2025
·
6 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
April 21, 2025
·
4 min read
Drug Development
Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022
Propella Therapeutics, Inc. (“Propella” or “the Company”) today announced that Dr. Jose Avitia of the New Mexico Cancer Center will present data from the Company’s ongoing Phase 1/2 trial of PRL-02 for the treatment of advanced prostate cancer on Sunday, September 11 at 12:00 pm at the European Society for Medical Oncology (ESMO) Congress 2022.
September 8, 2022
·
4 min read
1 of 71,327
Next
